Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
16 Mar 2016
|
| In: |
Leukemia and lymphoma
Year: 2016, Jahrgang: 57, Heft: 7, Pages: 1723-1726 |
| ISSN: | 1029-2403 |
| DOI: | 10.3109/10428194.2015.1113274 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.3109/10428194.2015.1113274 Verlag, lizenzpflichtig, Volltext: https://www.tandfonline.com/doi/full/10.3109/10428194.2015.1113274 
|
| Verfasserangaben: | Mark-Alexander Schwarzbich, Tilman Schöning, Martin Cremer, Katharina Lisenko, Anthony D. Ho, Matthias Witzens-Harig |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1698845162 | ||
| 003 | DE-627 | ||
| 005 | 20220818100617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200526s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3109/10428194.2015.1113274 |2 doi | |
| 035 | |a (DE-627)1698845162 | ||
| 035 | |a (DE-599)KXP1698845162 | ||
| 035 | |a (OCoLC)1341326519 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schwarzbich, Mark-Alexander |d 1983- |e VerfasserIn |0 (DE-588)143268236 |0 (DE-627)64435867X |0 (DE-576)335999263 |4 aut | |
| 245 | 1 | 0 | |a Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment |c Mark-Alexander Schwarzbich, Tilman Schöning, Martin Cremer, Katharina Lisenko, Anthony D. Ho, Matthias Witzens-Harig |
| 264 | 1 | |c 16 Mar 2016 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.05.2020 | ||
| 700 | 1 | |a Schöning, Tilman |d 1972- |e VerfasserIn |0 (DE-588)140330836 |0 (DE-627)617702489 |0 (DE-576)316456705 |4 aut | |
| 700 | 1 | |a Cremer, Martin |e VerfasserIn |0 (DE-588)1084363852 |0 (DE-627)848800796 |0 (DE-576)456316078 |4 aut | |
| 700 | 1 | |a Kriegsmann, Katharina |d 1986- |e VerfasserIn |0 (DE-588)1049422449 |0 (DE-627)781924006 |0 (DE-576)40339774X |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Witzens-Harig, Mathias |e VerfasserIn |0 (DE-588)1050736516 |0 (DE-627)784812322 |0 (DE-576)404988970 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia and lymphoma |d London [u.a.] : Taylor & Francis Group, 1989 |g 57(2016), 7, Seite 1723-1726 |h Online-Ressource |w (DE-627)324746237 |w (DE-600)2030637-4 |w (DE-576)099718170 |x 1029-2403 |7 nnas |a Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment |
| 773 | 1 | 8 | |g volume:57 |g year:2016 |g number:7 |g pages:1723-1726 |g extent:4 |a Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment |
| 856 | 4 | 0 | |u https://doi.org/10.3109/10428194.2015.1113274 |x Resolving-System |x Verlag |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.tandfonline.com/doi/full/10.3109/10428194.2015.1113274 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200526 | ||
| 993 | |a Editorial | ||
| 994 | |a 2016 | ||
| 998 | |g 1050736516 |a Witzens-Harig, Mathias |m 1050736516:Witzens-Harig, Mathias |d 910000 |d 910100 |e 910000PW1050736516 |e 910100PW1050736516 |k 0/910000/ |k 1/910000/910100/ |p 6 |y j | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1049422449 |a Kriegsmann, Katharina |m 1049422449:Kriegsmann, Katharina |d 910000 |d 910100 |e 910000PK1049422449 |e 910100PK1049422449 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1084363852 |a Cremer, Martin |m 1084363852:Cremer, Martin |d 910000 |d 910100 |e 910000PC1084363852 |e 910100PC1084363852 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 140330836 |a Schöning, Tilman |m 140330836:Schöning, Tilman |d 910000 |e 910000PS140330836 |k 0/910000/ |p 2 | ||
| 998 | |g 143268236 |a Schwarzbich, Mark-Alexander |m 143268236:Schwarzbich, Mark-Alexander |d 910000 |d 910100 |e 910000PS143268236 |e 910100PS143268236 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1698845162 |e 367135108X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment","title_sort":"Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment"}],"language":["eng"],"person":[{"role":"aut","given":"Mark-Alexander","display":"Schwarzbich, Mark-Alexander","family":"Schwarzbich"},{"family":"Schöning","display":"Schöning, Tilman","given":"Tilman","role":"aut"},{"display":"Cremer, Martin","given":"Martin","role":"aut","family":"Cremer"},{"family":"Kriegsmann","role":"aut","given":"Katharina","display":"Kriegsmann, Katharina"},{"role":"aut","given":"Anthony Dick","display":"Ho, Anthony Dick","family":"Ho"},{"family":"Witzens-Harig","display":"Witzens-Harig, Mathias","role":"aut","given":"Mathias"}],"name":{"displayForm":["Mark-Alexander Schwarzbich, Tilman Schöning, Martin Cremer, Katharina Lisenko, Anthony D. Ho, Matthias Witzens-Harig"]},"physDesc":[{"extent":"4 S."}],"id":{"doi":["10.3109/10428194.2015.1113274"],"eki":["1698845162"]},"relHost":[{"language":["eng"],"part":{"issue":"7","pages":"1723-1726","extent":"4","volume":"57","text":"57(2016), 7, Seite 1723-1726","year":"2016"},"title":[{"title":"Leukemia and lymphoma","title_sort":"Leukemia and lymphoma"}],"pubHistory":["1.1989/90 -"],"recId":"324746237","origin":[{"publisherPlace":"London [u.a.] ; London [u.a.]","dateIssuedKey":"1989","publisher":"Taylor & Francis Group ; Informa Healthcare","dateIssuedDisp":"1989-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 08.09.15"],"id":{"eki":["324746237"],"issn":["1029-2403"],"zdb":["2030637-4"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatmentLeukemia and lymphoma"}],"note":["Gesehen am 26.05.2020"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"16 Mar 2016"}],"recId":"1698845162"} | ||
| SRT | |a SCHWARZBICEFFICACYAN1620 | ||